Abstract
Alterations of the intracellular ubiquitin–proteasome pathway are found in neurodegenerative and inflammatory disorders of the central nervous system, as well as in its malignancies. Inhibitory substrates of the proteasomes represent promising approaches to control autoimmune inflammations and induction of apoptosis in cancer cells. Extracellular circulating proteasomes are positively correlated to outcome prognosis in hematogenic neoplasias and the outcome in critically ill patients. Previously, we reported raised levels of proteolytic active 20S proteasomes in the extracellular alveolar space in patients with acute respiratory distress syndrome (ARDS). For the cerebrospinal fluid, we assumed that extracellular circulating proteasomes with enzymatic activity can be found, too. Cerebrospinal fluid (CSF) samples of twenty-six patients (14 females, 12 males), who underwent diagnostic spinal myelography, were analyzed for leukocyte cell count, total protein content, lactate and interleukine-6 (Il-6) concentrations. CSF samples were analyzed for concentration and enzymatic activity of extracellular 20S proteasomes (fluorescenic substrate cleavage; femtokatal). Blood samples were analyzed with respect to concentration of extracellular circulating proteasomes. Choroidal plexus was harvested at autopsies and examined with immunoelectron microscopy (EM) for identification of possible transportation mechanisms. Statistical analysis was performed using SPSS (18.0.3). In all patients, extracellular proteasome was found in the CSF. The mean concentration was 24.6 ng/ml. Enzymatic activity of the 20S subunits of proteasomes was positively identified by the fluorescenic subtrate cleavage at a mean of 8.5 fkat/ml. Concentrations of extracellular proteasomes in the CSF, total protein content and Il-6 were uncorrelated. Immunoelectron microscopy revealed merging vesicles of proteasomes with the outer cell membrane suggestive of an exozytic transport mechanism. For the first time, extracellular circulating 20S proteasome in the CSF of healthy individuals is identified and its enzymatic activity detected. A possible exozytic vesicle-bond transportation mechanism is suggested by immunoelectron microscopy. The present study raises more questions on the function of extracellular proteasome in the CSF and encourages further studies on the role of extracellular protesomes in pathological conditions of the central nervous system (tumor lesions and inflammatory processes).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andonian S, Jarvi K, Zini A, Hermo L (2002) Ultrastructural features of the vas deferens from patients undergoing vasectomy and vasectomy reversal. J Androl 23(5):691–701
Bachmann HS, Novotny J, Sixt S et al (2010) The G-allele of the PSMA6-8C > G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels. Eur J Haematol 85(2):108–113
Baumeister W, Walz J, Zuhl F, Seemuller E (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92(3):367–380
Beyer NH, Milthers J, Bonde Lauridsen AM, Houen G, Lautrup Frederiksen J (2007) Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis. Scand J Clin Lab Invest 67(7):696–706
Borissenko L, Groll M (2007) 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 107(3):687–717
Brancolini C (2008) Inhibitors of the ubiquitin–proteasome system and the cell death machinery: how many pathways are activated? Curr Mol Pharmacol 1(1):24–37
Cecarini V, Ding Q, Keller JN (2007) Oxidative inactivation of the proteasome in Alzheimer’s disease. Free Radic Res 41(6):673–680
Ciechanover A (1998) The ubiquitin–proteasome pathway: on protein death and cell life. EMBO J 17(24):7151–7160
Copley SD (2003) Enzymes with extra talents: moonlighting functions and catalytic promiscuity. Curr Opin Chem Biol 7(2):265–272
Coux O, Tanaka K, Goldberg AL (1996) Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 65:801–847
Dahlmann B, Ruppert T, Kloetzel PM, Kuehn L (2001) Subtypes of 20S proteasomes from skeletal muscle. Biochimie 83(3–4):295–299
Dang LC, Melandri FD, Stein RL (1998) Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 37(7):1868–1879
Dutaud D, Aubry L, Henry L et al (2002) Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods 260(1–2):183–193
Fujita Y, Mori I, Kitano S (1983) Color reaction between pyrogallol re-molybdenum (VI) complex and protein. Bunseki Kagaku 32:E379–E386
Gaczynska M, Rock KL, Goldberg AL (1993) Role of proteasomes in antigen presentation. Enzyme Protein 47(4–6):354–369
Gaspar N, Sharp SY, Eccles SA et al (2010) Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 9(5):1219–1233
Gillardon F, Kloss A, Berg M et al (2007) The 20S proteasome isolated from Alzheimer’s disease brain shows post-translational modifications but unchanged proteolytic activity. J Neurochem 101(6):1483–1490
Glickman MH, Ciechanover A (2002) The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82(2):373–428
Goldberg AL (2007) Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35(Pt 1):12–17
Goodale RL, Goetzman B, Visscher MB (1970) Hypoxia and iodoacetic acid and alveolocapillary barrier permeability to albumin. Am J Physiol 219(5):1226–1230
Grimm LM, Osborne BA (1999) Apoptosis and the proteasome. Results Probl Cell Differ 23:209–228
Groll M, Ditzel L, Lowe J et al (1997) Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386(6624):463–471
Guillaume B, Chapiro J, Stroobant V et al (2010) Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 107(43):18599–18604
Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479
Hilt W, Wolf DH (1996) Proteasomes: destruction as a programme. Trends Biochem Sci 21(3):96–102
Jakob C, Egerer K, Liebisch P et al (2007) Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 109(5):2100–2105
Jeffery CJ (1999) Moonlighting proteins. Trends Biochem Sci 24(1):8–11
Jeffery CJ (2003) Moonlighting proteins: old proteins learning new tricks. Trends Genet 19(8):415–417
Keller JN, Markesbery WR (2000) Proteasome inhibition results in increased poly-ADP-ribosylation: implications for neuron death. J Neurosci Res 61(4):436–442
Keller JN, Hanni KB, Markesbery WR (2000a) Impaired proteasome function in Alzheimer’s disease. J Neurochem 75(1):436–439
Keller JN, Hanni KB, Markesbery WR (2000b) Possible involvement of proteasome inhibition in aging: implications for oxidative stress. Mech Ageing Dev 113(1):61–70
King RW, Deshaies RJ, Peters JM, Kirschner MW (1996) How proteolysis drives the cell cycle. Science 274(5293):1652–1659
Kinoshita M, Hamakubo T, Fukui I, Murachi T, Toyohara H (1990) Significant amount of multicatalytic proteinase identified on membrane from human erythrocyte. J Biochem 107(3):440–444
Kisselev AF, Goldberg AL (2001) Proteasome inhibitors: from research tools to drug candidates. Chem Biol 8(8):739–758
Kloss A, Henklein P, Siele D et al (2009) The cell-penetrating peptide octa-arginine is a potent inhibitor of proteasome activities. Eur J Pharm Biopharm 72(1):219–225
Kopp F, Hendil KB, Dahlmann B, Kristensen P, Sobek A, Uerkvitz W (1997) Subunit arrangement in the human 20S proteasome. Proc Natl Acad Sci USA 94(7):2939–2944
Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R (1995) Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268(5210):533–539
Ludwig H, Khayat D, Giaccone G, Facon T (2005) Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 104(9):1794–1807
Mayo I, Arribas J, Villoslada P et al (2002) The proteasome is a major autoantigen in multiple sclerosis. Brain 125(Pt 12):2658–2667
Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96(18):10403–10408
Nickel W (2005) Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 6(8):607–614
Niedermann G, King G, Butz S et al (1996) The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides. Proc Natl Acad Sci USA 93(16):8572–8577
Oh P, Borgstrom P, Witkiewicz H et al (2007) Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung. Nat Biotechnol 25(3):327–337
Olanow CW, McNaught KS (2006) Ubiquitin–proteasome system and Parkinson’s disease. Mov Disord 21(11):1806–1823
Parton RG, Simons K (2007) The multiple faces of caveolae. Nat Rev Mol Cell Biol 8(3):185–194
Roth GA, Moser B, Krenn C et al (2005) Heightened levels of circulating 20S proteasome in critically ill patients. Eur J Clin Invest 35(6):399–403
Schoch B, Regel JP, Nierhaus A et al (2008) Predictive value of intrathecal interleukin-6 for ventriculostomy-related Infection. Zentralbl Neurochir 69(2):80–86
Sixt SU, Dahlmann B (2008) Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta 1782(12):817–823
Sixt SU, Peters J (2010) Extracellular alveolar proteasome: possible role in lung injury and repair. Proc Am Thorac Soc 7(1):91–96
Sixt SU, Beiderlinden M, Jennissen HP, Peters J (2007) Extracellular proteasome in the human alveolar space: a new housekeeping enzyme? Am J Physiol Lung Cell Mol Physiol 292(5):L1280–L1288
Sixt SU, Adamzik M, Spyrka D et al (2009) Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 179(12):1098–1106
Stein RL, Melandri F, Dick L (1996) Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 35(13):3899–3908
Thuy-Tien H, Haugen M, Aarseth J, Storstein A, Vedeler CA (2008) Proteasome antibodies in patients with cancer or multiple sclerosis. Scand J Immunol 67(4):400–403
Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015–1068
Yousef AA, Suliman GA, Mabrouk MM (2010) The value of correlation of serum 20S proteasome concentration and percentage of lymphocytic apoptosis in critically ill patients: a prospective observational study. Crit Care 14(6):R215
Acknowledgment
The authors appreciate the excellent technical assistance of G. Ladwig with the immunoelectron microscopy.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mueller, O., Anlasik, T., Wiedemann, J. et al. Circulating Extracellular Proteasome in the Cerebrospinal Fluid: A Study on Concentration and Proteolytic Activity. J Mol Neurosci 46, 509–515 (2012). https://doi.org/10.1007/s12031-011-9631-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-011-9631-2